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In addition to Gag, Pol, and Env, primate lentiviruses encode other virion-associated proteins, including Vpr, Vpx, and
Vif. Vpr- and Vpx-staphylococcal nuclease and chloramphenicol acetyltransferase fusion proteins incorporate into human
immunodeficiency virus (HIV) virions and retain enzyme activity when expressed in trans with HIV proviruses (Wu et al., J.
Virol. 69, 3389, 1995). To explore whether the viral protease (PR) could be expressed as a proteolytically active fusion
protein, the HIV PR coding region was fused in-frame with the HIV-2 vpx and HIV-1 vpr genes. Using a vaccinia virus-T7
expression system, the Vpx-PR fusion protein was expressed and formed homodimers. Coexpression with Pr55Gag demon-
strated that Vpx-PR possessed Gag-specific proteolytic activity and inhibited the production of Gag virus-like particles.
Trans-expression of a PR-Vpr fusion protein with HIV-1 provirus caused a profound reduction in viral protein expression
and virion production. Importantly, the PR-Vpr fusion protein caused a similar level of inhibition and intracellular cleavage
of Pr55Gag precursor protein when coexpressed with protease defective HIV-1 provirus. The inhibitory effect of PR-Vpr
expression on virion production was markedly greater than that of PR alone. These results indicate that Vpr augments the
intracellular proteolytic activity of PR when expressed as a fusion protein and thus may be relevant for the expression of
PR in intracellular immunization strategies against HIV infection. Moreover, the ability to express and package enzymatically
active PR-Vpr fusion protein, independent of Gag/Pol, may provide a novel means to study enzyme function. q 1996 Academic
Press, Inc.
The human immunodeficiency virus (HIV) Gag and Pol causes premature PR activation, induces extensive intra-
cellular cleavage of Gag/Pol, and inhibits virus particleproteins are synthesized as precursor polyproteins that
formation (15, 27, 32). Factors that influence PR dimeriza-are cleaved into mature products by the viral protease
tion also affect PR activity. Proteolytically active PR has(4, 16, 19, 35). The Gag precursor protein (Pr55Gag) is
been expressed as linked single-chain dimers andprocessed to yield matrix, capsid, nucleocapsid (NC),
multimers (5, 15). HIV-1 proviruses that express single-and p6. The Pol precursor is processed into protease
chain PR dimers or multimers in cis are defective in(PR), reverse transcriptase (RT), and integrase (IN). The
particle formation and exhibit extensive intracellular pro-virus-coded enzymes (PR, RT, and IN) are synthesized in
cessing of the Gag precursor protein (1, 20). The expres-the context of the Gag/Pol polyprotein that is expressed
sion of PR in trans with HIV-1 provirus also inhibits virusby a ribosomal frameshift (12). Assembly of the Gag and
particle formation and infectivity (1, 23). In transient co-Gag/Pol precursors at the plasma membrane augments
transfection experiments, Swartz et al. demonstrated aactivation of the viral PR and subsequently the maturation
40-fold decrease in the production of infectious virusof infectious virions. Strict control of PR activation limits
when HIV-1 was coexpressed in trans with PR (23). Arrigopremature intracellular processing of Gag and Gag/Pol
and Huffman demonstrated that the expression of PR asand thus facilitates efficient virus production.
a linked multimer in T-cell lines inhibited HIV-1 replica-Limited expression of PR within the context of the Gag/
tion by several orders of magnitude (1). By monitoringPol precursor polyprotein and the fact that it must dimer-
Gag cleavage, Arrigo and Huffman also demonstratedize to be active are factors thought to play important roles
that the expression of PR as an intramolecular multimerin the regulation of PR activation and early function (26,
resulted in a large increase in PR activity in comparison30, 31, 34). Overexpression of PR from proviral DNA (mu-
with the level obtained when PR was expressed as atated to place gag and pol in the same reading frame)
monomer. The expression of PR as a linked dimer or
multimer has also been shown to be cytotoxic (1, 20).
Similar to these findings, Zybarth and Carter have re-1 To whom correspondence and reprint requests should be ad-
dressed at University of Alabama at Birmingham, Department of Medi- ported that the proteolytic activity of a eukaryotically ex-
cine, 701 South 19th Street, LHRB 639, Birmingham, AL 35294. Fax: pressed NC-PR fusion protein correlates with its ability
(205) 975-7300. E-mail: hema021@uabdpo.dpo.uab.edu.
to dimerize (47).
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Regulated trans-expression of PR has been suggested
as a gene therapy strategy against HIV infection (1, 23).
The HIV Vpr and Vpx proteins exhibit biologic and physi-
cal properties that could impact on the development of
such an antiretroviral strategy. Vpr and Vpx are acces-
sory proteins that are incorporated into virions (3, 9, 13,
44, 45). Both subcellular localization and virion incorpora-
tion of Vpr and Vpx are mediated by interaction with their
cognate Gag precursor protein (14, 17, 21, 22, 33, 40).
Sequences within the C-terminal p6 region of Pr55Gag
mediate their packaging (17, 22, 40). Vpr and Vpx exhibit
nucleophilic properties (22, 24, 25, 41, 43), and together
with the p17 matrix protein, Vpr facilitates movement of
the viral preintegration complex into the nucleus of nondi-
viding cells (8). Migration of Vpr in nondenaturing gels
at twice the molecular weight as the monomeric protein FIG. 1. Construction of Vpx-PR and PR-Vpr expression plasmids. (A)
suggests that it may dimerize (33, 46). Recent studies Illustration of the fusion junction of the pTM-vpxPR expression plasmid.
An NcoI/SstI DNA fragment containing the HIV-2ST vpx coding sequencefrom our laboratory demonstrated that staphylococcal
was amplified by the polymerase chain reaction (PCR) and ligated intonuclease and chloramphenicol acetyltransferase can be
the pTM-1 vector, generating pTM-vpx. The 3* antisense PCR primer
expressed as enzymatically active fusion protein with Vpr changed the vpx transnational stop codon (TAA) to a serine residue
and Vpx (42). Moreover, these fusion proteins interact (Ser) and substituted the C-terminal valine (Val) with arginine (Arg). An
SstI/SalI DNA fragment containing the HIV-2ST PR coding sequencewith Gag and incorporate into virions, even in the pres-
was amplified by PCR and ligated into pTM-vpx at the SstI/XhoI restric-ence of wild-type Vpr and Vpx proteins. In this study we
tion sites. (B) Illustration of the fusion junction of the pLR2P-PRvprpresent data that demonstrate proteolytic activity of PR
expression plasmid. A DNA fragment encompassing the HIV-1SG3 prote-when expressed as a fusion with either Vpx or Vpr. ase (PR) coding sequence was amplified by PCR using primers con-
To explore whether PR could be expressed as an enzy- taining NcoI and SstI restriction sites. This PCR product was digested
with NcoI and SstI and ligated into the pLR2P expression plasmid,matically active fusion protein the HIV-1 PR coding region
generating pLR2P-PR. An SstI/XhoI DNA fragment encompassing thewas fused in-frame with the HIV-2 vpx gene (Fig. 1A) and
HIV-1SG3 vpr gene was then amplified by PCR and ligated into pLR2P-placed under control of the T7 promoter in the high- PR. This placed vpr downstream and in-frame of PR, generating the
efficiency pTM-1 expression vector (29). This recombi- pLR2P-PRvpr expression plasmid.
nant plasmid (designated pTM-vpxPR) was transfected
into HeLa cells that were infected with recombinant vac-
cinia virus-T7 (rVT7), using methods described previously have also reported that PR is autoproteolytic at a site(s)
(39). As controls, the pTM-1 and pTM-vpx2 expression near its N-terminus (2, 37). The expression of a proteolyti-
vectors were also transfected. The pTM-vpx2 vector ex- cally active Vpx-PR fusion protein was further suggested
presses the wild-type HIV-2ST vpx gene (42). Twenty by accelerated cytopathic effects noted in HeLa cell cul-
hours after transfection, cells were washed twice with tures transfected with pTM-VpxPR, compared to those
phosphate-buffered saline and lysed. Soluble proteins transfected with either pTM-1 or pTM-vpx (data not
were separated by SDS–PAGE and subjected to immu- shown).
noblot analysis. Both anti-Vpx and anti-PR antibodies de- To investigate whether an HIV PR inhibitor would affect
tected a protein of approximately 26 kDa in pTM-vpxPR- the expression of Vpx-PR, transfected HeLa cells were
transfected cells (Fig. 2A). This protein migrated at the also cultured in medium supplemented with a 4 mM con-
expected position based on calculations of the combined centration of the HIV protease inhibitor L-689,502 (kindly
molecular weights of the Vpx (15 kDa) and PR (11 kDa) provided by Dr. Emini, Merck Co.). Under these condi-
fusion protein partners. Detection of the 26-kDa Vpx-PR tions, the 26-kDa Vpx-PR fusion protein was detected
fusion protein with anti-Vpx and anti-PR antibodies indi- in increased amounts using both anti-Vpx and anti-PR
cated the expression of both Vpx and PR reading frames. antibodies, while the amount of Vpx detected remained
Anti-Vpx antibodies also detected the 15-kDa Vpx protein approximately the same (Fig. 2B). Moreover, the 18-kDa
in cells transfected with pTM-vpx2. Interestingly, the anti- anti-Vpx antibody-reactive protein was no longer de-
tected. These results suggest that the Vpx-PR fusion pro-Vpx antibody also detected a protein of approximately
tein is able to form a proteolytically active molecule that18 kDa in pTM-vpxPR-transfected cells. Since the anti-
can be inhibited by an HIV-specific protease inhibitor.Vpx antibody is specifically reactive to epitopes within
the first 19 N-terminal amino acid residues (13), this find- The formation of a homodimer is required for PR activ-
ing suggested Vpx-PR was enzymatically active and auto- ity and function. To examine whether the Vpx-PR could
be detected as a dimer, lysates prepared from HeLa cellsproteolytic at a site within the N-terminus of PR. Others
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FIG. 2. Immunoblot analysis of Vpx-PR expression in mammalian cells. (A) Expression of the Vpx-PR fusion protein. The pTM-vpxPR expression
vector was transfected into HeLa cells 1 hr after infection with recombinant vaccinia virus-T7 (rVT7), at a multiplicity of infection equal to 10. As
controls, the pTM-1 and pTM-vpx vectors were also transfected into HeLa cells. Cell lysates were prepared 20 hr after transfection and examined
by immunoblot analysis as previously described (39). Replica blots were probed separately with anti-Vpx and anti-PR specific rabbit antisera. Anti-
Vpx antiserum was raised against the N-terminal 19-amino-acid residues of the HIV-2ST Vpx protein (13) and anti-PR antiserum was generated
against a full-length prokaryotically expressed PR protein (Wu et al., in press). (B) Expression of Vpx-PR in the presence of HIV protease inhibitor.
Replica-transfected cell cultures (to those described in A) were cultured for 20 hr in medium supplemented with a 4 mM concentration of the L-
689,502 protease inhibitor. Replica blots were prepared from cell lysates and probed separately with anti-Vpx and anti-PR antibodies. (C) Expression
of Vpx-PR under nonreducing conditions. The pTM-vpxPR and pTM-vpx expression vectors were transfected separately into replica cultures of rVT7-
infected HeLa cells. The culture medium was supplemented with a 4 mM concentration of L-689,502. Twenty hours after transfection, one of the
cell culture pairs was lysed and examined by immunoblot analysis under reducing conditions (R), while the other was prepared and analyzed under
nonreducing conditions (NR). Blots were probed with anti-Vpx antiserum. Proteins were detected using the enhanced chemiluminescence (ECL,
Amersham) method as described by the manufacturer.
transfected with pTM-vpxPR, and cultured for 20 hr in a Recent studies have indicated that trans-expression of
4 mM concentration of L-689,502, were analyzed under HIV-1 PR can cause premature intracellular processing
reducing and nonreducing conditions. L-689,502 was of the Gag precursor protein and block the production
used to stabilize expression and thus to increase the of extracellular virus particles (1, 23). To investigate how
amount of Vpx-PR available for analysis. Under nonre- expression of Vpx-PR would affect the production of vi-
ducing conditions, immunoblot analysis detected the 26- rus-like particles (VLPs) pTM-vpxPR was cotransfected
kDa Vpx-PR fusion protein and an additional protein mi- into HeLa cells with pTM-gag2. Since HIV-2 PR can also
grating at approximately 52 kDa. Under these conditions
higher molecular weight species of anti-Vpx antibody-
reactive proteins were also detected. Under reducing
conditions, only the 26-kDa Vpx-PR fusion protein and
the 14-kDa Vpx protein were specifically detected (Fig.
2C). Taken together, these results suggest that the Vpx-
PR fusion protein is able to form a homodimeric complex
that is proteolytically active.
To test whether the Vpx-PR fusion protein could cleave
the Pr55Gag precursor protein, the HIV-2 Gag expression
plasmid pTM-gag2 (40) was cotransfected with pTM-
vpxPR into rVT7-infected HeLa cells. As a control, pTM-
gag2 was transfected alone. Twenty hours later, the cell
monolayers were lysed and examined by immunoblot
analysis. In lysates prepared from cotransfected cells,
Gag monoclonal antibodies detected a predominance of
p27 capsid protein (Fig. 3A). The Pr55Gag precursor pro-
FIG. 3. Gag-specific PR activity of the Vpx-PR fusion protein. Thetein was predominant in cells transfected with pTM-gag2.
HIV-2 Gag expression plasmid pTM-gag2 was transfected alone andExpression of Vpx-PR was confirmed in cotransfected
cotransfected with pTM-vpxPR into HeLa cells 1 hr after infection withcells by probing a replica blot with anti-Vpx antibodies
rVT7. Cell lysates were prepared 20 hr later and examined by immu-
(Fig. 3B). These results demonstrate that the Vpx-PR fu- noblot analysis. Replica blots were probed with either Gag monoclonal
sion protein possesses intracellular protease activity and antibody (A) or anti-Vpx antiserum (B). Bound antibodies were detected
using the ECL detection system.specifically cleaves the HIV Pr55Gag precursor protein.
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cotransfected with SG3 proviral DNA. Forty-eight hours
later, culture supernatants were collected and subjected
to ultracentrifugation over cushions of 20% sucrose. Pel-
lets were lysed and examined by immunoblot analysis.
Coexpression of both PR and PR-Vpr with HIV-1 markedly
reduced the detection of supernatant virus (Fig. 5A). In
repeated experiments (three independent analyses), HIV-
1 p24 antigen ELISA demonstrated reductions of approxi-
mately 50- and 10,000-fold by coexpression of the PR
and PR-Vpr proteins with SG3 provirus, respectively (data
not shown). Identical results were also obtained when
PR was expressed as a fusion protein with Vpr in the
opposite orientation (Vpr-PR, data not shown). In order
to examine whether the viral encoded protease contrib-
uted to the inhibition of virus production, through prema-
ture intracellular Gag/Pol cleavage and PR activation in-
FIG. 4. Vpx-PR fusion protein inhibits the production of virus-like
duced by expression of PR-Vpr, a protease defective HIV-particles. HeLa cells infected with rVT7 were transfected with pTM-
1 provirus (PM3; 16) was analyzed in parallel experi-Gag1 and pTM-Gag2 alone and in combination with pTM-vpxPR. Cul-
ture supernatants were collected 24 hr later, clarified by low-speed ments with HIV-1SG3 . Coexpression of PR-Vpr and PR
centrifugation (1000 g, 10 min), and ultracentrifuged (125,000 g, 2 hr) with PM3 reduced the production of PM3 virions to an
over cushions of 20% sucrose. Pellets were lysed and examined by extent similar to that observed when coexpressed with
immunoblot analysis. Replica blots were probed with either Gag mono-
SG3 (Fig. 5B). This result indicated that coexpression ofclonal antibody (A) or anti-Vpx antiserum (B). Bound antibodies were
the PR-Vpr fusion protein with HIV-1 dramatically inhib-detected using the ECL detection system.
ited the production of virus particles. Moreover, this ex-
periment was repeated three times and each time the
extent to which PR-Vpr inhibited HIV-1 particle formationcleave the HIV-1 Pr55Gag precursor protein, the HIV-1 Gag
expression plasmid, pTM-gag1 (40), was also cotrans- was markedly greater than that of PR.
The effect of PR-Vpr on the production of HIV-1 fromfected with pTM-vpxPR. As controls, pTM-gag2 and pTM-
gag1 were transfected alone. Twenty hours later, culture transfected cells was assessed further by separately co-
transfecting different concentrations (ranging from 8 tosupernatants were clarified by low-speed centrifugation
(1000 g, 10 min) and VLPs were pelleted by ultracentrifu- 0.5 mg) of pLR2P-PRvpr with constant amounts of SG3
gation (125,000 g, 2 hr) through 20% cushions of sucrose.
Immunoblot analysis of the pellets indicated a significant
reduction in the production of both Gag1 and Gag2 VLPs
when coexpressed with the Vpx-PR fusion protein (Fig.
4A). Interestingly, in repeated experiments (two indepen-
dent analyses) both Vpx-PR (Fig. 4B) and p27 capsid
protein were detected in VLPs derived from cultures co-
transfected with pTM-gag2 and pTM-vpxPR, suggesting
that Vpx-PR associated with VLPs and cleaved the Gag
polyprotein after assembly, at least partially. These re-
sults indicate that expression of a proteolytically active
Vpx-PR fusion protein inhibits the production of both HIV-
1 and HIV-2 Gag VLPs.
To explore whether it was possible to inhibit the pro-
duction of HIV-1 virions by trans-expression of the PR-
Vpr fusion protein, the HIV-1SG3 (7) PR coding sequence
was fused in-frame with the HIV-1YU-2 vpr gene and li- FIG. 5. PR-Vpr expression inhibits HIV-1 virion production. Monolayer
gated into the HIV-regulated pLR2P eukaryotic expres- cultures of HLtat cells (6) were transfected with equal amounts (4 mg)
sion vector, generating pLR2P-PRvpr (Fig. 1B). The pLR2P of HIV-1SG3 (A) and HIV-1PM3 (B) proviral DNAs, alone and in combination
with the pLR2P-PRvpr and pLR2P-PR expression vectors, respectively.expression vector contains the HIV-2 LTR and RRE ele-
Forty-eight hours later, culture supernatants were collected, clarifiedments and facilitates high-level expression of other Vpr
by low-speed centrifugation, and subjected to ultracentrifugationand Vpx fusion proteins expressed in trans with HIV pro-
(125,000 g, 2 hr) over cushions of 20% sucrose. Pellets were lysed
viruses (42). The pLR2P-PRvpr vector was cotransfected and examined by immunoblot analysis. Blots were probed with Gag
with HIV-1SG3 provirus into HLtat cells. For comparison, monoclonal antibodies. Bound antibodies were detected using the ECL
detection system.the pLR2P-PR expression vector (Fig. 1, legend) was also
AID VY 7890 / 6a15$$$582 04-04-96 15:11:49 vira AP: Virology
311SHORT COMMUNICATION
and 6C) and the production of virions from transfected
cells (Fig. 5). The inhibitory effect of PR-Vpr on virus pro-
duction was dosage dependent, resulting in dramatic
decreases in the detection of extracellular virions when
higher concentrations were used for transfection (Figs.
6B and 6D). To assess the relative impact of the PR-Vpr
fusion protein on the production of SG3 virions, PR-Vpr
was also coexpressed with a PR defective virus (PM3).
An equally profound inhibitory effect on the expression
of virus protein and the production of PM3 virions was
observed (Fig. 6), indicating that inhibition was primarily
a function of the PR-Vpr fusion protein and not premature
cleavage and activation of the viral protease. These re-
sults clearly demonstrate that the Vpx-PR and PR-Vpr
fusion proteins possess PR enzyme activity and inhibit
HIV multiplication when expressed in trans.
There are two lines of evidence that indicate that the
PR component (and not Vpr) of the PR-Vpr fusion protein
was responsible for virus inhibition. First, coexpressionFIG. 6. Dosage response effect of PR-Vpr on viral protein expression
and virion production. Monolayer cultures of HLtat cells were of other Vpr and Vpx fusion proteins with HIV proviruses
transfected with HIV-1SG3 (A and C) and HIV-1PM3 (B and D) proviral does not decrease intracellular viral protein expression
DNAs, alone and in combination with twofold dilutions (ranging from or virion production (42); and second, the coexpression
0.5 to 8 mg) of pLR2P-PRvpr. Forty-eight hours later, virions were pel-
of an enzymatically inactive Vpr-mutant-PR with HIV-1leted from culture supernatants by ultracentrifugation (125,000 g, 2 hr)
provirus did not inhibit virion production (Fig. 7). Our datathrough 20% cushions of sucrose. Pellets and cell monolayers were
lysed and examined by immunoblot analysis. Blots were probed with suggest that the dominant mechanism by which PR-Vpr
monoclonal antibody to the HIV-1 capsid protein. Bound antibodies inhibits virion production is through its cytotoxic effects
were detected using the ECL detection system. on cells (Fig. 6). HIV PR is known to cleave several cellu-
lar substrates, including cytoskeletal proteins (10), micro-
tubule-associated proteins (38), calmodulin, and the tran-and PM3 proviral DNAs (4 mg). As controls, SG3 and
PM3 were also transfected alone. Forty-eight hours later, scription factor NFkB (36). Immunoblot analysis of
transfected cell lysates revealed a dosage response ef-cell monolayers and pellets of supernatant virions were
lysed and examined by immunoblot analysis. Transfec- fect of PR-Vpr on the expression of Gag protein, thus
indicating cytotoxic properties of the PR-Vpr fusion pro-tion of increasing concentrations of pLR2P-PRvpr re-
sulted in the expression of decreasing amounts of Gag tein (Figs. 6A and 6C). It is also possible that PR-Vpr
induces premature intracellular cleavage of the Gag andprotein (Figs. 6A and 6C). Decreasing amounts of intra-
cellular Gag protein expression correlated with reduced Gag/Pol precursor proteins, resulting in defective virion
assembly and extracellular release.virion production (Figs. 6B and 6D). It was interesting to
note that PR-Vpr expression induced cleavage of the PM3 Since others have shown that the expression of PR in
trans with HIV-1 can inhibit virus multiplication (1, 23),Gag precursor protein, giving rise to p24 capsid protein
(detectable in cell lysates) and disproportionate amounts we included PR in selected experiments for comparison
with PR-Vpr. This analysis indicated that both PR andof p49 and p41 proteins. These results demonstrate that
PR-Vpr cleaves the Gag precursor protein and inhibits PR-Vpr inhibited the production of HIV-1 virions (Fig. 5).
Our results are in general agreement with published dataviral protein expression and virion production in a dos-
age-dependent manner. showing that PR expression inhibits virion production by
approximately 40-fold (23). Importantly, our results indi-This report demonstrates that the HIV protease is enzy-
matically active when expressed as a fusion protein with cated that the PR-Vpr fusion protein exerts a more potent
inhibitory effect than PR, and the detection of virions ineither Vpr or Vpx. Using the high-efficiency vaccinia virus-
T7 system, the Vpx-PR fusion protein was shown to effi- culture supernatants was reduced by greater than
10,000-fold. We have considered several possibilitiesciently cleave the HIV Gag precursor protein, and p27
capsid protein was the predominant cleavage product that may account for this difference. Expression of the
Gag precursor protein is known to be sufficient for local-detected (Fig. 3A). The PR-Vpr fusion protein was also
proteolytically active, as demonstrated by its ability to ization of Vpr and Vpx on the cell surface membrane and
virion packaging (14, 22). In radioimmunoprecipitationcleave Pr55Gag when coexpressed in trans with a PR
defective HIV-1 provirus (Fig. 6C). An additional indicator assays, Pr55Gag has been shown to coprecipitate with
Vpr and Vpx protein (11, 21). These data suggest thatfor the proteolytic activity of PR-Vpr was its inhibitory
effect both on the expression of viral protein (Figs. 6A Pr55Gag and PR-Vpr localize to the same subcellular com-
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Pol and thus may represent a novel means to study PR
function. Because PR-Vpr expression is cytotoxic, such
an approach will necessitate PR mutants with reduced
toxicity. A number of PR mutants that partially reduce
enzyme activity without altering substrate binding have
been described (18, 28). Proviruses containing these mu-
tants can be expressed in mammalian cells and produce
partially infectious virions with mature core structures
(18). Using the recombinant vaccinia virus-T7 system,
we have already demonstrated packaging of the Vpx-PR
fusion protein into HIV-2 Gag virus-like particles, and the
detection of p27 in pellets may suggest processing of
Gag protein after VLP assembly and release (Fig. 4B).
Moreover, we have also demonstrated efficient packag-
ing of an enzymatically defective PR-mutant-Vpr (As-
p25Asn) fusion protein into HIV-1 virions (Fig. 7). These
results suggest that it may also be possible to packageFIG. 7. Packaging of PRM-Vpr fusion protein into HIV-1 particles by
trans-complementation. Monolayer cultures of HLtat cells were proteolytically active fusion proteins into virions if intra-
transfected with HIV-1SG3 proviral DNAs alone and in combination with cellular PR activity can be controlled. The ability to pack-
the PRM-Vpr (pLR2P-PRMvpr) and PR (pLR2P-PR) expression plasmids. age functional virus-encoded enzymes independent of
The pLR2P-PRMvpr expression vector was generated by mutagenizing
Gag/Pol, via virion-associated accessory proteins, repre-PR at position 25, changing the aspartic acid residue to an asparagine.
sents a novel and potentially a useful method that couldForty-eight hours later, culture supernatants were subjected to ultra-
centrifugation over cushions of 20% sucrose and examined by immu- contribute toward both the study of viral enzyme function
noblot analysis. Replica blots were probed with either anti-Vpr antise- and the development of gene therapy-based antiretrovi-
rum (A) or Gag monoclonal antibodies (B). Bound antibodies were ral strategies.
detected using the ECL detection system.
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